Top 50 Biotech VC (Venture Capital) Funds in Belgium in October 2023

Portfolio highlights

• IVEX — At IVEX, we are creating a safety co-pilot to make existing decision making platforms for autonomous driving safe. Our technology is based on years of research performed at KU Leuven University in Belgium. Our unique IP and team experience in behavior planning and functional safety enables the development of safe and reliable autonomous systems toreduce the traffic victims to zero by 2030.
• Funkey — Kies je teambuilding uit meer dan 500 onvergetelijke activiteiten. Wij zorgen voor de volledige organisatie, incl. eventuele catering en overnachting.
• dScribe — dScribe is your one-stop-shop to catalog, document and discover anything data-related.No more spending hours looking for the right data.No more doubting about the meaning of your KPIs.Reach the next level of data maturity by offering your users a single entry point to find, understand and access all your reports & data, no matter wherethey are stored.

Portfolio highlights

• Univercells — Univercells delivers novel biomanufacturing platforms and solutions aiming at making biologics available & affordable to all.
• Intressa Vascular — Intressa Vascular SA is a medical device company committed to providing innovative solutions to life-threatening cardiovascular conditions such as aortic dissection
• Santero Therapeutics — Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms.

Portfolio highlights

• VoxelSensors — Novel sensor architecture designed for low latency and low power 3D perception.
• Morrow Optics — Looking for the next big thing in eyewear technology? Check out Morrow's electrified progressives, also known as autofocals! These innovative glasses switch focus length with a touch of button, providing you with seamless vision from near to far. Learn more about this technology on Morrow's website.
• Swave Photonics — Our mission is to bring the metaverse to life and enable display manufacturers and content creators to disrupt the visualization market with immersive, ultra-high-resolution, lifelike, true holographic displays.

Portfolio highlights

• AstriVax — AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline.
• Precirix — Developing radio-immunotherapeutic drugs for cancer patients.
• Sibylla Biotech — Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.

Portfolio highlights

• ERS — ERS is a semiconductor manufacturing company that offers thermal wafer testing and Air-Cool technology services.
• Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.
• Complement Therapeutics — Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Geographic atrophy (late dry age-related macular degeneration) is a chronic eye condition that affects millions - and for which there is

Portfolio highlights

• DName-iT — DName-iT is a genetic analysis tool that offers DNA-based barcode labeling technology and a software platform that can ensure reliable, cost-effective NGS specimen identification.
• MyCellHub — MyCellHub.com is a pre-startup from the KULeuven in the biotherapeutics industry that aspires to reform the way cell production processes are organised. With a regulatory compliant Saas-platform for data management and analytics, we increase the efficiency of your manufacturing processes, provide actionable insights via cell culture specificprocess analytics and facilitate regulatory compliance by means of a real-time audit trail and automated batch records.
• Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

Portfolio highlights

• BOTALYS — BOTALYS uses an innovative Biomimetic Indoor Farming technology to recreate the ideal wild conditions for rare botanicals to grow in. We develop pristine & potent botanical ingredients for the Nutraceutical and Cosmetic industries.
• Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
• Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.

Portfolio highlights

• Animab — Animal Health Company
• Aphea.Bio — Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptakeof nutrients from the soil.
• Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.

Portfolio highlights

• Axithra — Saving lives and improving health economics through significant advancement of therapeutic drug monitoring (TDM).
• RISORCE — RISORCE fills a need in Belgium for local solutions for processing tire waste while remaining dedicated to a circular economy strategy. We provide a regionally-based, technologically and environmentally sound solution.
• Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).

Portfolio highlights

• Qviro — Compare industrial robotics and brands based on user ratings, product prices, use-cases. Reviews for Collaborative robots, Cobots, Industrial robots
• Cumul.io — Create powerful dashboards in minutes. Share with your teams, or integrate in your platform. Drive growth in your business today!
• MobieTrain — The mobile microlearning platform of Mobietrain improves knowledge retention with personalised, gamified learning to boost your sales.

Portfolio highlights

• Chainels — The tenant experience app for every property in your portfolio. Save time, gain insights and collaborate with your tenants all in one place.
• VoxelSensors — Novel sensor architecture designed for low latency and low power 3D perception.
• fruitcore robotics — fruitcore robotics is a robotic system that leverages intelligent software and innovative mechatronics.

Portfolio highlights

• CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
• Scenic Biotech — We are pioneers in the discovery of genetic modifiers to enable the development of transformative therapeutics.
• Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Portfolio highlights

• AdipoPharma — By harnessing the power of the Adipocyte AdipoPharma is committed to developing innovative treatment for type 2 diabetes
• AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
• Santero Therapeutics — Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms.

Portfolio highlights

• Iktos — Iktos is the only company to offer generative modeling with built-in synthetic accessibility for successful drug discovery
• DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
• The Exploration Company — For Space & Non-Space Industries.

Portfolio highlights

• cikisi — Specialized in Web Intelligence (collecting, searching and filtering web information). Help companies and organizations to take advantage of Web information that are relevant to their development. Develops and commercializes Cikisi WMT, a Web Intelligence Solution.
• AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
• Santero Therapeutics — Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms.

Portfolio highlights

• Paperspace — Ceres, Inc. (Ceres) is an agricultural biotechnology company selling seeds to produce renewable biomass feedstocks. The Company’s large-scale commercial products are sweet sorghum varieties that can be used as a drop-in feedstock to extend the operating season of Brazilian sugarcane-to-ethanol mills. Its products include sweet sorghum, high biomasssorghum, switchgrass, miscanthus and row crops. Its energy crops can also be used for the production of second-generation biofuels and bio-based chemicals, including cellulosic ethanol, butanol, jet fuel, diesel-like molecules and gasoline-like molecules, from non-food biomass. Baseload utility scale electric power can also be generated from the biomass feedstocks grown from its seeds. Ceres has sold switchgrass and high biomass sorghum seeds in the United States under its Blade Energy Crops (Blade) brand. In January 2010, the Company incorporated a subsidiary, Ceres Sementes do Brasil Ltda.
• Discai — Discai unburdens financial institutions with innovative AI applications so they can focus on what they are really good at!
• Setle — During the renovation process, Settle assists in helping to make better judgments. Settle's goal is to increase renovation transparency. From increasing the energy efficiency of your home to getting the most out of your housing budget.

Portfolio highlights

• VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
• Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
• Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.

Portfolio highlights

• Caliopa — Caliopa NV develops and markets silicon photonics based optical transceivers for the data and telecommunications markets. The company was incorporated in 2010 and is based in Zwijnaarde, Belgium.
• Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
• Trinean — Unchained Labs helps biologics & gene therapy researchers break free from tools that don't cut it. Crank up your research with our problem-solving products.

Portfolio highlights

• QurAlis — QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS .
• Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
• Actio Biosciences — At Actio, we are leveraging advances in genetics and precision medicine to develop life-changing treatments that target underlying shared biology between rare and common diseases. We are applying expertise in genetics, drug discovery, and data sciences to pinpoint targets that not only cause rare diseases with high unmet need, but that also hold promise in more common indications.

Portfolio highlights

• DrugBank — DrugBank augments human intelligence to improve the world’s health. Our suite of products are powered by the world’s most complete and up-to-date pharmaceutical knowledge database. It includes everything there is to know about drugs and how they work in the body. We enable companies to improve healthcare delivery through precision medicine orclinical software applications, as well as uncover insights through data science in drug discovery. Our knowledge base can be integrated into software solutions to help achieve clinical intelligence. Companies can easily scale their usage through our API and launch faster with flexible data modules. By providing users with advanced insights and the right information at the right time, users are empowered to make better health decisions.Our extensive, structured datasets are used to discover novel drug candidates, identify drug repurposing opportunities, and build predictive machine learning models. Companies working with data science can find answers quickly and get drugs to market faster with our evidence-based drug information. Lastly, our publicly available resource, DrugBank Online, is free-to-use with limited datasets available for download for academic and non-commercial researchers. DrugBank has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.
• HypnoVR — HypnoVR is a virtual reality software for anesthesia, treatment of pain, and anxiety. It was founded in 2016 and is based in Strasbourg, France.
• Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.

Portfolio highlights

• Dim3 — Improve patients outcome - Deliver actionable insights - Save healthcare costs
• Elysia — Elysia developed solution dedicated to quality control laboratories for the production of Radio Pharmaceuticals.
• Convert Pharmaceuticals — Convert Pharmaceuticals develops prodrugs that are inert upon administration to patients, but transform into potent anti-cancer agents upon entering tumors.

Portfolio highlights

• eTheRNA immunotherapies — eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases.
• AstriVax — AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline.
• Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.

Portfolio highlights

• Paragraf — We Work to Develop Innovative and Useful End Products from Novel Materials. Our Analogue Sensors Are Designed to Provide Accurate Field Gradient Mapping & Alignment.
• Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
• NorthSea Therapeutics — NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generatedpipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.

Portfolio highlights

• moveUP — Ontvang medische zorg op afstand voor en na uw operatie. moveUP is gespecialiseerd in de begeleiding van knie- en heupoperaties.
• Axithra — Saving lives and improving health economics through significant advancement of therapeutic drug monitoring (TDM).
• Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.

Portfolio highlights

• DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
• smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
• Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

Portfolio highlights

• CluePoints — CluePoints' Risk-Based Quality Management (RBQM) Software illuminates risks that could compromise patient safety, and enables compliance with ICH E6 (R2).
• A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
• Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.

Portfolio highlights

• BiOceanOr — BiOceanOr provides underwater weather stations to measure water quality. Their solutions provide informations from your exploitation in real-time. Receive alerts in real-time and take decisions with their preventive alert system.
• myskillcamp — Myskillcamp is a digital learning platform and educational design support service. Myskillcamp supports their customers in the digital transformation of their company and the launch of their Digital Learning project. From the audit of needs to the design of engaging educational devices, through a pilot phase, they make a point of honor to adapt thedigital to the specificities of each and give it meaning.With their online platform, businesses can manage their learner communities and connect all their partners in one place. Their tool also allows businesses to structure training spaces by skills, trades, brands within camps. In parallel, businesses can create educational content from scratch, select a map in their marketplace, or plan sessions in-class. Businesses can organize the distribution of their training to a single learner or to a whole group.
• Octave — A sustainable, cost-effective and reliable energy storage system with second-life batteries from electric vehicles.

Portfolio highlights

• Abcuro — Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
• Precirix — Developing radio-immunotherapeutic drugs for cancer patients.
• ARMGO,Pharma,Inc. — ARMGO Pharma, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat debilitating cardiac, skeletal muscular, and neurological disorders. It offers rycals, which are calcium release channel stabilizers that act on ryanodine receptor/calcium release channel, a therapeutic target located on thesarcoplasmic/endoplasmic reticulum of the cell for treating chronic heart failure, cardiac arrythmias, and muscle disorders, as well as cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. The company was incorporated in 2004 and is based in Tarrytown, New York with an additional office in New York, New York.

Portfolio highlights

• Opinum — What is Opinum Data Hub? Our Data Hub is a secured Cloud-based platform that allows energy and environmental actors to centralise, enhance, analyse, and share data.
• Digiteal — Digiteal offers a wide range of services for e-invoice presentment, electronic payments and open banking.
• NietsCo — NietsCo. is the home of Botaniets Gin 0.0%, a leading selection of alcohol-free products, carefully distributed to the world's best restaurants, concept stores, shops and consumers.

Portfolio highlights

• Astraveus — Designing and building closed, automated, bioprocessing systems for the production of cell and gene therapies.
• Orikine Bio — Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders.
• Anoat Therapeutics — Anoat Therapeutics develops an innovative, disease-modifying approach in Cystic Fibrosis.

Portfolio highlights

• Apitope — Worg Pharmaceuticals has acquired all of the assets of Apitope International NV. You will be automatically redirected to www.worgpharma.com in ? seconds or click the link now. Worg Pharmaceuticals (Hangzhou) Co., Ltd.
• Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
• Okapi Sciences — Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases. The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination ofindividuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises.

Portfolio highlights

• Animab — Animal Health Company
• Virovet — Antiviral drugs and thermostable vaccines for livestock
• Aphea.Bio — Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptakeof nutrients from the soil.

Portfolio highlights

• Accelleran — Accelleran is pioneering a disruptive approach to the delivery of cost-effective, carrier and mission-critical grade TDD and FDD Small Cell networks through its focus on software quality and partnerships with volume manufacturers.Accelleran provides LTE Small Cell software and LTE Small Cell product solutions which address the real-worldchallenges of volume deployment of Small Cells. We offer turnkey solutions and unique experience on the challenges of integrating cellular technology on low cost, yet powerful platforms and architectures. Accelleran offers its customers solid and dependable system solutions, backed by the support of our unparalleled expertise.Accelleran’s technology is genuinely independent from any HW platform and enables operators to invest once in the integration and validation of a common software base that can be deployed across different segments, platforms and Small Cell architectural approaches to enable a truly integrated HetNet.
• Silicon Line — Munich, Germany-based Silicon Line (www.silicon-line.com) is the unchallenged world leader in developing and providing innovative ultra-low-power optical link technology that enables the use of thin, long, lightweight and very high speed ‘active’ optical cables for a wide array of consumer electronics products – including TVs, set-top boxes, videogame consoles, augmented reality (AR) and virtual reality (VR) headsets and related devices – as well as commercial and industrial applications. ‘Active’ refers to powered electronics integrated within the cable.Clear evidence of Silicon Line’s global leadership in ultra-lower-power optical technology can be seen not only by its steadily evolving line of leading-edge and industry-first products – with more than 25 different products now in use – but also in its pivotal role within the HDMI Forum, where it has successfully led efforts to enhance support for active optical cable technology standards in the latest specification, HDMI 2.1.Founded in 2005 as an outsource integrated circuit (IC) design house, Silicon Line quickly developed proven expertise in ultra-low-power, analog and mixed-signal chip design. Billions of ICs based on its designs have been used in products of major brand-name manufacturers.
• Silicon Mobility — Our solution enables carmakers to improve EV and HEV energy efficiency, increase range and accelerate charging time while reducing cost.

Portfolio highlights

• SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
• TISSIUM — TISSIUM is creating the future of tissue reconstruction. Learn more about our novel solutions based on our proprietary platform of biomorphic programmable polymers.
• Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

Portfolio highlights

• VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
• Dualyx — Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.
• CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.

Portfolio highlights

• Aloxy — Aloxy offers reliable IIot solutions tailored to the needs of the process industry. Our valve sensor provides an open and close indication of manual valves.
• Graftys — Graftys, an Aix-en-Provence, France-based early stage company focused on advanced bone biologics.
• SENSE in — SENSE in manufactures monitoring solutions based on thermomechanical sensors sensitive to deformation, pressure, temperature, humidity, and more. Their solutions evaluate in real time or periodically the expected characteristics and alert on abnormal behavior, threshold overruns, and damage.

Portfolio highlights

• Octave — Octave is a national behavioral health practice that’s creating a new standard for care delivery that’s both high-quality and accessible to more people. With in-person and virtual clinics in California and New York, the company offers personalized care plans that can include individual therapy, couples therapy, and groups, while pioneeringrelationships with payers to make care more affordable through insurance. Grounded in science, Octave enables clients to experience profound change that is as measurable as it is meaningful.
• Acesion Pharma — Acesion Pharma ApS is a Danish biotech company founded in 2011 and based in Copenhagen. Acesion Pharma develops more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.
• Alentis Therapeutics — Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases.

Portfolio highlights

• Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
• Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
• Tenpoint Therapeutics — Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.

Portfolio highlights

• MMI — The future of Microsurgery: microinstruments that expand the possibilities of surgical interventions. Wristed robotic microinstruments for unprecedented results in microsurgery.
• Vivasure Medical — Medical device company developing a closure device for vascular access procedures.
• Ermium Therapeutics — Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation.

Portfolio highlights

• CellFE — CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.
• BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
• Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.

Portfolio highlights

• Finquest — Finquest is the premier deal origination provider delivering personalized connections to its clients who seek M&A and direct investment opportunities in Europe, North America, and APAC.With a unique database, machine learning and a team of experts, Finquest provides targeted, curated and actionable connections, whilst maintaining completeconfidentiality throughout the process. With Finquest, clients can broaden their market access, creating a more efficient deal-making environment.Finquest is headquartered in Singapore and has offices in New York, London, Paris, Frankfurt, Luxembourg, Bangalore, and Hong Kong.
• Sensolus — Introducing our smart, industrial-grade tracking solution. With battery life of up to ten years, and no additional infrastructure needed.
• EclecticIQ — EclecticIQ is a global threat intelligence, hunting and response technology provider. Its clients are some of the most targeted organizations, globally. To build tomorrow’s defenses today, they have to understand the threats against them – and align their efforts and investments to mitigate their risks. EclecticIQ helps governments, largeenterprises and service providers manage threat intelligence, create situational awareness and adopt an intelligence-led cybersecurity approach. EclecticIQ extended its focus towards hunting and response with the acquisition of Polylogyx’s endpoint technology in 2020. Founded in 2014, EclecticIQ operates globally with offices across Europe, North America, and via value-add partners. More info: www.eclecticiq.com

Portfolio highlights

• LEND — LEND provides peer to peer lending in Switzerland. It connects investors with borrowers. Moreover, investors earn substantial returns and borrowers benefit from low interest rates. The company is based in Switzerland and it was founded in 2015.
• AVAtronics — AVA Active Noise Cancellation (ANC) Solution is a breakthrough in Audio Industry. AVA is the first and only TRUE WIDE-BAND ANC in the market capable of selectively cancelling all annoying noises we want to get rid of without compromising the quality of Music or speech.
• Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.

Portfolio highlights

• Splice Bio — We are working with our proprietary platform to address key limitations of current gene therapy approaches to treat patients in need.
• Switch Therapeutics — Switch Therapeutics is a biotech company dedicated to revolutionizing RNA interference (RNAi) therapies with conditionally activated siRNAs (CASi).
• Code Biotherapeutics — Code Biotherapeutics is an emerging next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases not well served by other gene therapy technologies.

Portfolio highlights

• ROME Therapeutics — ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.
• Arialys Therapeutics — Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience. The company focuses on how the immune system impacts CNS health, disease, and treatment.
• Rapport Therapeutics — Precision medicines to match the complexity of the human brain.

Portfolio highlights

• AstriVax — AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline.
• Medikabazaar — Medikabazaar is an online B2B marketspace for medical supplies and equipment. They are a single point of contact for all product-based needs, enabling medical institutions and individual practitioners alike to cut down on operational costs and making the best global brands available locally, all aided with the miracle that goes by the name oftechnology. They are connected with more than 50,000 medical establishments, 1,50,000 Independent Practitioners, and have partnered with 13,000+ suppliers all over India including ones in Tier 2, Tier 3 cities, and remoter locations to establish a strong foothold in India and simultaneously earn the respect of our clients. With the power of technology, we organized a haywire market in a country with perhaps the largest and most complex geographical structure in the world for this purpose. Our last-mile delivery system and 26 strategically placed Fulfilment Centres across India enable us to deliver essential medical supplies to healthcare facilities and help them nurture quality and timely patient care. With our first international office in the Middle East, we are transcending boundaries to deliver care, everywhere.
• Indigo Diabetes — Revolutionizing the management of chronic disease.

Portfolio highlights

• Cohabs — Cohabs is a network of beautiful shared homes for nomads around the world. It provides flexible and fully furnished accommodations through a network of sustainable and community-driven shared homes. Cohabs prioritizes the experience of its members through a tech-centric and flexible process. They build a thriving community through monthly events,dinners, and other parties.
• Univercells — Univercells delivers novel biomanufacturing platforms and solutions aiming at making biologics available & affordable to all.
• Tangent Works — Create predictive models in seconds for faster and better forecasting & anomaly detection with TIM InstantML.

Portfolio highlights

• Sdui — Sdui is the solution for mobile communication in schools. With amazingly easy features for messaging, timetables and a wide range of third party integrations, the app digitizes processes and reduces administrative effort. Within two years, Sdui has reached hundreds of institutions and grown a serious reputation in the educational market.
• Ukio — Artfully designed fully furnished apartments available for extended stays
• FINBOURNE Technology — FINBOURNE Technology was founded in December 2016 with a mission to reduce the cost of investing and increase transparency for everyone. The company has grown from seven founders to over 130 people in less than five years. Our SaaS-native solutions offer greater agility and control, designed to deliver a new standard for data management, with afaster time to market. Built as a bitemporal engine and using open APIs, LUSID® ingests and translates data across organisations’ existing operational stack and wider ecosystem. The data platform supports IBOR, ABOR, tax-lot accounting, valuation and risk workflows. While, Luminesce®, a data virtualisation engine, solves the need to find and securely gather an extended world of data in real-time, enabling deeper insights and analytics. Together, they cover a depth of critical data management processes, for start-up managers, through to global investment institutions.

Portfolio highlights

• Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
• ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
• Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Portfolio highlights

• Ekompany — Ekompany is a Dutch producer of coated mineral fertilisers (CRF) with sales operations in Western Europe and Far East. Their team of professionals possesses the latest knowledge across the chemical, agricultural and horticultural fields and have decades of experience in designing, producing and supplying specialty fertilisers supported by the rightadvice.Established in 2010, their unique production facility in Born was opened for production in September 2013. Ekompany has developed a patented coating process that is clean, safe, continuous and more energy efficient than existing ones. This way they can produce intelligent Controlled Release Fertilisers that are both technologically advanced and economical for wider use in agriculture and horticulture. Learn more about their Ekote portfolio which has proven its benefits in more than 200 field trials internationally.
• FABPulous — FABPulous is an innovative healthcare company which develops and markets solutions for diagnostics in primary care and emergency medicine.FABPulous is a company based in The Netherlands. It was spun out of Maastricht University at the end of 2008. In December 2009 FABPulous closed a first equity financing round co-led by Thuja Capital, HealthInnovations, Limburg Ventures and NV Industriebank LIOF.The company has developed a technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages in the point-of-care (POC) and home testing setting, over current technology. It concerns a disposable plasma preparation device that can be integrated with many IVD detection platforms, such lateral flow devices. The first product application under development by FABPulous is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), to aid in the first-line diagnosis of acute myocardial infarction.
• Kriya Materials — Kriya Materials is the innovative developer and manufacturer of various metal oxide nano particles as well as their downstream dispersions and functional coating products thereof. Coatings play an important role in our everyday life, although often not recognized by those who do not master the art. Coatings are a big market and many products fallunder this category. Kriya Materials focuses itself on the development and manufacturing of various nano metal oxides which it uses internally for the development and production of very high end coatings.The coatings made by Kriya Materials are applied in a wide range of markets, some examples are the Plasma Panel and LCD industry, from Smartphone to touch panels to glass surfaces.

Portfolio highlights

• Vianode — Vianode is a producer of sustainably engineered battery materials.
• Devnya Cement — Devnya Cement is a cement company that operates in the wholesale construction products industry.
• Angelini Pharma — Angelini is committed to identifying health solutions with a prevalent focus on the areas of Central Nervous System (CNS), including pain, and Rare Diseases. The Company is also a leading player in the Consumer Health sector,